SRR17866821
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 49.5
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.630
- E2F_TARGETS+0.560
- MYC_TARGETS_V2+0.560
- OXIDATIVE_PHOSPHORYLATION+0.560
- DNA_REPAIR+0.470
- MTORC1_SIGNALING+0.460
- G2M_CHECKPOINT+0.430
- INTERFERON_ALPHA_RESPONSE+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MYOGENESIS-0.350
- ANGIOGENESIS-0.330
- KRAS_SIGNALING_DN-0.330
- UV_RESPONSE_DN-0.320
- APICAL_JUNCTION-0.310
- APICAL_SURFACE-0.310
- WNT_BETA_CATENIN_SIGNALING-0.300
- COAGULATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 81b828aa-cb06-4790-ba3e-efaa39f4eeef | — | — | 0.961 |
| 2 | SRR27320678 | — | — | 0.934 |
| 3 | ddd65fce-1a39-415c-9114-7a9c8e9b266c | — | — | 0.915 |
| 4 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.897 |
| 5 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.893 |
| 6 | BS_W80TJC27 | Supratentorial Ependymoma | — | 0.885 |
| 7 | MNG277 | — | — | 0.881 |
| 8 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.879 |
| 9 | SRR11296765 | — | — | 0.878 |
| 10 | cdef9a7f-9daa-4a33-b196-08a12a2ed203 | — | — | 0.875 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.630 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.560 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.470 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.460 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |